Skip to main content
    W

    West Pharmaceutical Services Inc (WST)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE

    $417.95
    +1.53 (+0.37%)

    Market Cap: $29.01B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    West Pharmaceutical Services Inc (WST) Financials: Revenue, Profit and Cash Flow

    Updated Jul 23, 2026. Financial statements from company filings, amounts in US dollars.

    West Pharmaceutical Services reported revenue of $3.07B for the fiscal year ended Dec 31, 2025, up 6.3% from the year before. That year, net income was $493.70M with a net margin of 16.1%, operating cash flow was $754.80M and free cash flow was $468.90M. The quarter ended Jun 30, 2026 had revenue of $872.30M and net income of $154.00M.

    Revenue and Margins

    The operating margin was 19.0% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $1.51B, a compound annual rate of 8.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$3.07B+6.3%35.9%19.0%16.1%
    Dec 2024$2.89B-1.9%34.5%19.7%17.0%
    Dec 2023$2.95B+2.2%38.3%22.9%20.1%
    Dec 2022$2.89B+2.0%39.4%25.4%20.3%
    Dec 2021$2.83B+31.9%41.5%26.6%23.4%
    Dec 2020$2.15B+16.7%35.8%19.0%16.1%
    Dec 2019$1.84B+7.1%32.9%16.1%13.1%
    Dec 2018$1.72B+7.4%31.8%14.0%12.0%
    Dec 2017$1.60B+6.0%32.1%14.1%9.4%
    Dec 2016$1.51BN/A33.2%12.9%9.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income rose 0.2% from the year before. In the quarter ended Jun 2026, net income rose 16.8% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$3.07B$2.89B$2.95B$2.89B$2.83B$2.15B$1.84B$1.72B$1.60B$1.51B
    Cost of revenue$1.97B$1.89B$1.82B$1.75B$1.66B$1.38B$1.23B$1.17B$1.09B$1.01B
    Gross profit$1.10B$998.50M$1.13B$1.14B$1.18B$767.80M$605.70M$545.40M$512.90M$501.40M
    Research and development$74.30M$69.10M$68.40M$58.50M$52.80M$46.90M$38.90M$40.30M$39.10M$36.80M
    Operating income$584.90M$569.90M$676.00M$734.00M$752.30M$406.90M$296.60M$240.30M$225.80M$195.20M
    Net income$493.70M$492.70M$593.40M$585.90M$661.80M$346.20M$241.70M$206.90M$150.70M$143.60M
    EBITDA$755.30M$724.30M$816.30M$803.30M$878.40M$517.20M$399.90M$351.40M$325.60M$287.50M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$872.30M$844.90M$805.00M$804.60M$766.50M$698.00M$748.80M$746.90M$702.10M$695.40M$732.00M$747.40M
    Gross profit$329.20M$296.40M$303.90M$294.30M$273.90M$231.90M$273.60M$264.70M$230.00M$230.20M$278.20M$288.30M
    Operating income$179.10M$177.10M$156.60M$167.60M$153.70M$107.00M$159.60M$161.30M$126.20M$122.80M$160.90M$177.30M
    Net income$154.00M$138.80M$132.10M$140.00M$131.80M$89.80M$130.10M$136.00M$111.30M$115.30M$137.00M$161.30M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $225.50M by $565.80M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$4.27B$3.64B$3.83B$3.62B$3.31B$2.79B$2.34B$1.98B$1.86B$1.72B
    Current assets$1.98B$1.54B$1.94B$1.92B$1.74B$1.37B$1.06B$894.40M$743.50M$641.90M
    Cash and equivalents$791.30M$484.60M$853.90M$894.30M$762.60M$615.50M$439.10M$337.40M$235.90M$203.00M
    Total liabilities$1.09B$961.10M$948.50M$931.90M$978.40M$939.30M$768.20M$582.60M$582.90M$599.20M
    Short-term debt$22.70M$18.80M$134.00M$2.20M$44.20M$2.30M$2.30M$100.00K$0$2.40M
    Long-term debt$202.80M$202.60M$72.80M$206.70M$208.80M$252.90M$255.00M$196.00M$197.00M$226.20M
    Shareholder equity$3.18B$2.68B$2.88B$2.68B$2.34B$1.85B$1.57B$1.40B$1.28B$1.12B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$4.08B$4.11B$4.27B$4.11B$3.95B$3.62B$3.64B$3.68B$3.49B$3.60B$3.83B$3.75B
    Total liabilities$1.09B$1.12B$1.09B$1.05B$1.02B$935.10M$961.10M$923.00M$912.60M$921.70M$948.50M$886.50M
    Cash and equivalents$435.80M$521.40M$791.30M$628.50M$509.70M$404.20M$484.60M$490.90M$446.20M$601.80M$853.90M$898.60M
    Shareholder equity$2.99B$2.99B$3.18B$3.05B$2.93B$2.68B$2.68B$2.75B$2.58B$2.68B$2.88B$2.87B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 62.1% of operating cash flow. Dividends and share repurchases together came to 41.6% of it.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$754.80M$653.40M$776.50M$724.00M$584.00M$472.50M$367.20M$288.60M$263.30M$219.40M
    Capital expenditures$285.90M$377.00M$362.00M$284.60M$253.40M$174.40M$126.40M$104.70M$130.80M$170.20M
    Free cash flow$468.90M$276.40M$414.50M$439.40M$330.60M$298.10M$240.80M$183.90M$132.50M$49.20M
    Dividends paid$61.20M$59.10M$57.00M$54.10M$51.10M$48.10M$45.10M$42.10M$39.10M$35.80M
    Share repurchases$134.00M$560.90M$438.30M$202.80M$137.10M$115.50M$83.10M$70.80M$74.40M$52.20M
    Investing cash flow-$285.90M-$378.70M-$368.70M-$288.20M-$253.10M-$179.50M-$228.00M-$100.80M-$133.60M-$175.80M
    Financing cash flow-$185.10M-$622.60M-$459.60M-$293.60M-$168.10M-$137.10M-$36.80M-$80.70M-$109.00M-$113.90M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow$124.00M$89.90M$251.10M$197.20M$177.10M$129.40M$190.10M$180.10M$165.00M$118.20M$239.10M$230.10M
    Capital expenditures$43.20M$42.70M$76.10M$63.30M$75.20M$71.30M$104.90M$81.30M$100.20M$90.60M$108.70M$95.80M
    Free cash flow$80.80M$47.20M$175.00M$133.90M$101.90M$58.10M$85.20M$98.80M$64.80M$27.60M$130.40M$134.30M
    Last 12 quarters

    Frequently Asked Questions About WST

    What is West Pharmaceutical Services' annual revenue?

    West Pharmaceutical Services reported revenue of $3.07B for the fiscal year ended Dec 31, 2025.

    How fast is West Pharmaceutical Services' revenue growing?

    Revenue was up 6.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 2.1%.

    Is West Pharmaceutical Services profitable?

    Yes. West Pharmaceutical Services reported net income of $493.70M for the fiscal year ended Dec 31, 2025, with a net margin of 16.1%.

    How much free cash flow does WST generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $754.80M minus capital expenditures of $285.90M produced free cash flow of $468.90M.

    How much debt does West Pharmaceutical Services have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $202.80M, short-term debt of $22.70M and cash and equivalents of $791.30M.